drugset / Trial / NCT06395337
Multimodal Imaging in Rectal Cancer & Pancreatic Cancer
Phase 1/2
Unknown
20 enrolled
Radboud University Medical Center
Leiden University Medical Center · collab
NaSingle-groupOpen-labelOther
Summary
Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years. CEA-targeting tracers can be used for preoperative, intra-operative and postoperative imaging purposes. This study focusses on both preoperative and intraoperative multimodal imaging and image-guided surgery in patients with rectal cancer or pancreatic cancer.
Timeline
- Start
- 2024-05-02
- Primary completion
- 2025-05-02
- Completion
- 2025-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DOTA-ANTI-CEA antibody | Protein / enzyme biologic | — | Intravenous |